Firas B Badin, MD

Newark Beth Israel Med Ctr

University of Damascus School of Medicine

University of Kentucky Medical Center

Newark Beth Israel Med Ctr

American Board of Internal Medicine

American Board of Internal Medicine

• Baptist Health Richmond
• Baptist Health Lexington

• Advanced Non-Small Cell Lung Cancer; Metastatic Cancer

  Krystal 007: A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

  Trial Details
• Extensive-stage Small-cell Lung Cancer

  EMERGE 402: Stage IV observational study for adult patients with metastatic SCLC

  Trial Details
• Lung Cancer

  A081801-Alchemist Sub-Study: This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery.

  Trial Details
• Lung Cancer

  Alliance A151216: ALCHEMIST - Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

  Trial Details
• Lung Cancer

  ECOG-ACRIN E4512: A Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer

  Trial Details
• Non Small Cell Lung Cancer

  QUILT -2.023:A phase 2, open-label, randomized study of ALT-803 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for patients with metastatic NSCLC

  Trial Details
• Non Small Cell Lung Cancer

  Phase 2, Open-Label, Multicenter, Randomized, Multi-Drug Platform Study of Durvalumab Alone or in Combination with Novel Agents in Subject with Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (COAST)

  Trial Details
• Non Small Cell Lung Cancer

  BeiGene A317-A1217- 301: Phase 3, Randomized, Open-Label Study to Compare Tislelizumab (BGB-A317) Plus Anti-TIGIT Monoclonal Antibody BGB-A1217 Plus Concurrent Chemoradiotherapy (cCRT) Followed by Tislelizumab Plus BGB-A1217

  Trial Details
• Non Small Cell Lung Cancer; Triple Negative Breast Cancer; Melanoma; Head and Neck Cancer

  BA3021-001: Phase 1/2 dose escalation and dose expansion study of BA3021 alone and in combination with Nivo in patients with advanced solid tumors

  Trial Details
• Non-small Cell Lung Cancer

  EF-36/Keynote: A pilot, single arm, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer

  Trial Details
• Non-small Cell Lung Cancer (NSCLC)

  Pacific 9: A Phase III, double-blind, placebo-controlled, Randomized, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy

  Trial Details
• Non-small Cell Lung Cancer (NSCLC)

  BeiGene A317-A1217-302: A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, or Metastatic Non-Small Cell Lung Cancer

  Trial Details
• Non-small Cell Lung Cancer (NSCLC) (WIRB-22-0106)

  Skyscraper: A Phase II/III, Randomized, Double Blind, Placebo-Controlled Study of Tiragolumab in Combination with Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab

  Trial Details
• Non-small Cell Lung Cancer<br> Recurrent Non-small Cell Lung Cancer <br>Metastatic Non-small Cell Lung Cancer

  CA224-104: A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer

  Trial Details
• Non-Small-Cell Lung Cancer

  BA3011-002: A Phase 2 study of BA3011 alone and in combination with Nivolumab in adult patients with metastatic non-small cell lung cancer (NSCLC) who had prior disease progression on a PD-1/L-1 Inhibitor

  Trial Details
• NSC Lung Cancer

  Razor-Encore - A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay

  Trial Details
• Previously Treated Non-Small Cell Lung Cancer

  LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

  Trial Details
• Small Cell Lung Cancer

  MK3475-B99: A Phase 2 Study to Evaluate Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (Keynote-B99)

  Trial Details
• Small Cell Lung Carcinoma

  MK3475-B98: A Phase 1b/2 Study to Evaluate Efficacy and Safety of Pembrolizumab in Combination w Investigational Agents for Treatment of Participants With PD-1/L1- refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (Keynote-B

  Trial Details